191 related articles for article (PubMed ID: 37775462)
1. First clinical experiences with inclisiran in a real-world setting.
Mulder JWCM; Galema-Boers AMH; Roeters van Lennep JE
J Clin Lipidol; 2023; 17(6):818-827. PubMed ID: 37775462
[TBL] [Abstract][Full Text] [Related]
2. Inclisiran: A Review in Hypercholesterolemia.
Frampton JE
Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
[TBL] [Abstract][Full Text] [Related]
5. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
[TBL] [Abstract][Full Text] [Related]
6. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.
Makhmudova U; Schatz U; Perakakis N; Kassner U; Schumann F; Axthelm C; Stürzebecher P; Sinning DL; Doevelaar A; Rohn B; Westhoff T; Vogt A; Scholl M; Kästner U; Geiling JA; Stach K; Mensch J; Lorenz E; Paitazoglou C; Eitel I; Baessler A; Steinhagen-Thiessen E; Koenig W; Schulze PC; Landmesser U; Laufs U; Weingärtner O;
Clin Res Cardiol; 2023 Nov; 112(11):1639-1649. PubMed ID: 37422840
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
[TBL] [Abstract][Full Text] [Related]
8. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
Scheen AJ; Wallemacq C; Lancellotti P
Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
[TBL] [Abstract][Full Text] [Related]
9. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
Smith KW; White CM
J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
[TBL] [Abstract][Full Text] [Related]
10. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y
J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838
[TBL] [Abstract][Full Text] [Related]
11. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
[TBL] [Abstract][Full Text] [Related]
12. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease.
Nishikido T
Cardiovasc Diabetol; 2023 Jan; 22(1):20. PubMed ID: 36717882
[TBL] [Abstract][Full Text] [Related]
13. The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions.
Lehoux D; Kallend D; Wijngaard PLJ; Brown AP; Zerler B
Pharmacol Res Perspect; 2023 Apr; 11(2):e01080. PubMed ID: 37021909
[TBL] [Abstract][Full Text] [Related]
14. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
[TBL] [Abstract][Full Text] [Related]
16. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
17. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
18. Inclisiran: How Widely and When Should We Use It?
Pirillo A; Catapano AL
Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035
[TBL] [Abstract][Full Text] [Related]
19. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
[TBL] [Abstract][Full Text] [Related]
20. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS;
Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
